Authors: Franz X Kleber Harald Rittger Klaus Bonaventura Uwe Zeymer Jochen Wöhrle Raban Jeger Benny Levenson Sven MöbiusWinkler Leonhard Bruch Dieter Fischer Christian Hengstenberg Tudor Pörner Detlef Mathey Bruno Scheller
Publish Date: 2013/08/28
Volume: 102, Issue: 11, Pages: 785-797
Abstract
Drugcoated balloon catheters DCB are a new clinical treatment modality for coronary and peripheral artery disease The goal of the consensus group is to develop recommendations for the clinical use of DCB based on randomized clinical trials and the best available clinical evidence The present paper gives an update on the recommendations against the background of a variety of new data published since the first paper was presentedThe general concept of our recommendations for the coronary use of DCB includes the preparation of the lesion to facilitate drug delivery and to estimate the need for stent implantation especially after relevant dissections Lesion preparation includes conventional angioplasty In more complex lesions additional treatments and imaging or functional measurements are helpful In case of no flowlimiting dissection and an acceptable but not stentlike primary result DCB use without additional stent implantation may be considered The proposed advantages of the DCB only concept over a direct stent approach include reduced restenosis rates in indications where DES show limited efficacy the reduction of DAPT especially in patients with contraindications for prolonged DAPT and the option of leaving no foreign object behind resulting in vascular restoration with potentially plaque regression instead of neoatherosclerosisFranz X Kleber has received lecture fees and study grants from B Braun Harald Rittger has received speaker honoraria and study grants from B Braun Klaus Bonaventura has received lecture fees from B Braun Jochen Wöhrle has received lecture fees and study grants from B Braun Raban Jeger has received study grants from B Braun and travel support from Medtronic Biotronik and B Braun Dieter Fischer has received lecture fees from B Braun Bruno Scheller has received lecture fees from B Braun and Medtronic travel support from Medtronic and B Braun he was named on a patent application of Charite university hospital Berlin and is a shareholder of InnoRa GmbH Berlin
Keywords: